drugset / Trial / NCT05662904
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
Phase 1
Not yet recruiting
12 enrolled
German Cancer Research Center
University Hospital Dresden · collabUniversity Hospital Heidelberg · collab
NaSingle-groupOpen-labelTreatment
Summary
The study "GALAXY33" is an open-label, prospective, nonrandomized, one arm phase I clinical trial in which patients with relapsed AML after allogeneic hematopoietic stem cell transplantation will be transplanted with CD33-deleted CD34+ HSC derived from the initially matched family donor.
Timeline
- Start
- 2028-01
- Primary completion
- 2029-01
- Completion
- 2030-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion | Unknown | — | — |
| Subject | Gemtuzumab Ozogamicin | Monoclonal antibody | — | — |